A systematic review and meta-analysis on the use of traditional Chinese medicine compound kushen injection for bone cancer pain

Bao, Yanju; Yang, Liping; Bai, Hua; Hou, Wei; Shi, Zhan; Li, Weidong; Li, Conghuang; Chen, Cihui; Li, Rui; Qin, Yinggang; Lv, Wenliang

doi:10.1007/s00520-013-2063-5

Cited by 52 publications

(48 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another meta-analysis enrolled a total of 7 randomized controlled trials and 521 patients were identified and analyzed to assess the efficacy and safety of compound kushen injection (a preparation extracted from Radix sophorae flavescentis) for bone cancer pain. Compared with radiotherapy or bisphosphonates, compound kushen injection showed significant effects on improving pain relief in patients with bone cancer pain (93 16-34. trials indicated that acupuncture might be beneficial for alleviating cancer pain. In all, TCM interventions appear to have beneficial effects on pain secondary to bone metastases in patients.…”

Section: Painmentioning

confidence: 99%

The advantages of using traditional Chinese medicine as an adjunctive therapy in the whole course of cancer treatment instead of only terminal stage of cancer

Zhao

Zhou

et al. 2015

BST

367

268

View full text Add to dashboard Cite

Section: Painmentioning

confidence: 99%

The advantages of using traditional Chinese medicine as an adjunctive therapy in the whole course of cancer treatment instead of only terminal stage of cancer

Zhao

Zhou

et al. 2015

BST

367

268

View full text Add to dashboard Cite

“…Compound Kushen Injection consists of extracts of two herbs (Radix sophorae fl avescentis and Rhizoma smilacis glabrae) (67) and has a long history of use in China as a treatment for bone cancer pain. Yanju, et al (67) reviewed 7 RCTs (n=521) which evaluated compound kushen provided by injection.…”

Section: Evidencementioning

confidence: 99%

“…Yanju, et al (67) reviewed 7 RCTs (n=521) which evaluated compound kushen provided by injection. All seven studies demonstrated signifi cant reductions in pain.…”

Section: Evidencementioning

confidence: 99%

Complementary and alternative medicine therapies for chronic pain

Bauer

Tilburt

Sood

et al. 2016

Chin. J. Integr. Med.

View full text Add to dashboard Cite

Pain afflflicts over 50 million people in the US, with 30.7% US adults suffering with chronic pain. Despite advances in therapies, many patients will continue to deal with ongoing symptoms that are not fully addressed by the best conventional medicine has to offer them. The patients frequently turn to therapies outside the usual purview of conventional medicine (herbs, acupuncture, meditation, etc.) called complementary and alternative medicine (CAM). Academic and governmental groups are also starting to incorporate CAM recommendations into chronic pain management strategies. Thus, for any physician who care for patients with chronic pain, having some familiarity with these therapies-including risks and benefits-will be key to helping guide patients in making evidence-based, well informed decisions about whether or not to use such therapies. On the other hand, if a CAM therapy has evidence of both safety and efficacy then not making it available to a patient who is suffering does not meet the need of the patient. We summarize the current evidence of a wide variety of CAM modalities that have potential for helping patients with chronic pain in this article. The triad of chronic pain symptoms, ready access to information on the internet, and growing patient empowerment suggest that CAM therapies will remain a consistent part of the healthcare of patients dealing with chronic pain.

show abstract

“…In recent years, transarterial chemoembolization (TACE) is one of the preferred treatments for patients with PLC who are not suitable for surgery or postoperative recurrence. FFKS was extracted from the mixture of Sophora flavescens and Heterosmilacis Japonicae with the mass ratio of 7 than 3, Experimental studies showed that FFKS could inhibit tumor cell growth, alleviate pain, elevated white blood cell, anti-infection and protect the body immune function [2,3].Until now, Many clinical trials showed that FFKS-TACE can reduce the adverse reactions and improve quality of life for primary liver cancer (PLC). however, a multi-center, randomized, double-blind PlaceboControlled Trial of FFKS-TACE for Treatment of PLC have not been reported.…”

Section: Introductionmentioning

confidence: 99%

Meta-Analysis of Randomized Controlled Trial in Treating Primary Liver Cancer by Fufang Kushen Injection Combined with TACE

Li¹,

Fan²,

Sun³

2016

Proceedings of the 2015 4th International Conference on Sustainable Energy and Environmental Engineering

View full text Add to dashboard Cite

Abstract. Objective. To evaluate effectiveness and safety of Fufang Kushen Injection combined with transcatheter arterial chemoembolization (TACE) for primary liver cancer (PLC). Search Strategy. Electronic databases were searched until 2 July, 2015. Inclusion Criteria. We included randomized clinical trials about comparison between Fufang Kushen Injection combined with TACE (FFKS-TACE) and TACE alone for treatment of PLC. Data Extraction and Analyses. Study selection, data extraction, quality assessment, and data analyses were conducted according to Cochrane standards. Results. 19 randomized trials were included. Methodological quality of the included trials was evaluated as generally low. compared with TACE alone, Meta-analysis showed that FFKS-TACE significantly improved the effective rate, KPS, six-month, one-year and two-year survival; significantly reduced the incidence of nausea and vomiting, fever, myelosuppression, transminase increased, bilirubin increased and stomach ache. Conclusion. FFKS-TACE for PLC can not only improve the effectiveness rate, KPS and survival rate, but also reduce the incidence rate of the clinical adverse effects such as nausea and vomiting, fever, myelosuppression, hepatic injury and stomach ache. However, the conclusion needs to be proved by further experiments on account of the absence of high quality articles. But evidence remains weak, rigorously designed trials are warranted to confirm these results.

show abstract

A systematic review and meta-analysis on the use of traditional Chinese medicine compound kushen injection for bone cancer pain

Abstract: This systematic review showed positive but weak evidence of CKI for bone cancer pain because of the poor methodological quality and the small quantity of the included trials. Future rigorously designed RCTs are required.

Cited by 52 publications

References 38 publications

The advantages of using traditional Chinese medicine as an adjunctive therapy in the whole course of cancer treatment instead of only terminal stage of cancer

The advantages of using traditional Chinese medicine as an adjunctive therapy in the whole course of cancer treatment instead of only terminal stage of cancer

Complementary and alternative medicine therapies for chronic pain

Meta-Analysis of Randomized Controlled Trial in Treating Primary Liver Cancer by Fufang Kushen Injection Combined with TACE

Contact Info

Product

Resources

About